Larimar Therapeutics Inc.

NASDAQ: LRMR · Real-Time Price · USD
3.98
-0.28 (-6.57%)
At close: Aug 15, 2025, 2:59 PM

Larimar Therapeutics Cash Flow Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Net Income
-80.6M -36.95M -35.35M -50.64M
Depreciation & Amortization
318K 311K 318K 326K
Stock-Based Compensation
8.8M 7.62M 6.62M 5.47M
Other Working Capital
5.03M -2.11M 1.64M 3.72M
Other Non-Cash Items
-5.45M -1.93M -820K -15K
Deferred Income Tax
n/a n/a n/a n/a
Change in Working Capital
6.17M -2.51M 1.67M 2.75M
Operating Cash Flow
-70.76M -33.46M -27.57M -42.1M
Capital Expenditures
-515K -164K -100K -333K
Cash Acquisitions
n/a -33.52K 90.86K -24.5K
Purchase of Investments
-227.87M -101.23M -133.61M -8.25M
Sales Maturities Of Investments
143M 134.75M 42.75M 32.75M
Other Investing Acitivies
n/a 33.52K -90.86K 24.5K
Investing Cash Flow
-85.39M 33.35M -90.96M 24.17M
Debt Repayment
n/a n/a n/a n/a
Common Stock Repurchased
n/a n/a n/a n/a
Dividend Paid
n/a n/a n/a n/a
Other Financial Acitivies
77K 30K n/a n/a
Financial Cash Flow
161.88M 30K 75.26M 19.89M
Net Cash Flow
5.74M -76K -43.27M 1.95M
Free Cash Flow
-71.28M -33.62M -27.67M -42.44M